BioAtla BCAB
OTC BCAB
$1.80 -0.01 (-0.55%)
At close: Nov 10, 2026 · 4:00 PM EST

BioAtla (BCAB) Current Deferred Revenue (2019 - 2021)

Updated

BioAtla (BCAB) posted Current Deferred Revenue of $19.81 million for Q3 2021, unchanged from the prior quarter.

Analysis

BioAtla (BCAB) Current Deferred Revenue (2019 - 2021) Analysis & Trends

Since Q4 2020, BioAtla has reported Current Deferred Revenue for 4 quarters.

  • According to Business Quant data, Current Deferred Revenue for the three prior quarters was $19.81 million (Q2 2021), $19.81 million (Q1 2021) and $19.81 million (Q4 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 BioAtla 2.99 Mn -15.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 19.81 Mn
Jun 30, 2021 19.81 Mn
Mar 31, 2021 19.81 Mn
Dec 31, 2020 19.81 Mn
Dec 31, 2019 1.42 Mn
API Access

BioAtla Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BCAB&period=max&api_key=YOUR_API_KEY